Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ8JIK)

• Drug Name: Chenodiol Drug Info
• Synonyms: 474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum

Indication

Disease Entry	ICD 11	Status	REF
Cholelithiasis	DC11	Approved	[1]

• Cross-matching ID:
  PubChem CID: 10133
  ChEBI ID: CHEBI:16755
  CAS Number: CAS 474-25-9
  TTD Drug ID: DMQ8JIK
  VARIDT Drug ID: DR00524
  INTEDE Drug ID: DR0295
  ACDINA Drug ID: D00118

Molecule-Related Drug Atlas

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[11]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[12]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[13]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[14]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[15]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[16]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[17]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[18]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[19]
Turofexorate isopropyl	DM36ONA	Hyperlipidaemia	5C80	Phase 1	[20]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[21]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[22]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[25]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[27]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[28]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[22]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[29]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[40]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[41]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[42]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[43]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[44]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[44]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[45]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[46]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[47]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[48]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[33]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[36]
Metronidazole	DMTIVEN	Abscess		Approved	[37]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[38]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[39]

Drug(s) Affected By 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[56]

Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[57]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[58]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[60]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[57]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[62]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[63]

Drug(s) Affected By 11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[65]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[64]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[66]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[67]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[68]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[65]

Drug(s) Affected By Gastrotropin (FABP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[73]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[75]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[76]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[77]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[78]

Drug(s) Affected By Fibroblast growth factor 19 (FGF19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[74]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[81]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[8]

Drug(s) Affected By Serum paraoxonase/arylesterase 1 (PON1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[85]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[86]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[88]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[74]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[89]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[90]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[83]

Drug(s) Affected By Sterol regulatory element-binding protein 1 (SREBF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[91]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[92]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[93]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[94]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[95]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]

Drug(s) Affected By Sulfotransferase 2A1 (SULT2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[97]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[67]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[103]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[104]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[105]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[106]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[107]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[108]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[109]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[110]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[111]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]

Drug(s) Affected By ATP-binding cassette sub-family C member 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[113]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[114]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[115]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[116]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[120]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[121]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[122]

Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[123]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[124]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[125]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[126]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[128]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[129]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]

Drug(s) Affected By Sulfotransferase 1C2 (SULT1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[130]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[131]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[133]

Drug(s) Affected By Solute carrier family 22 member 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[134]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[135]
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[136]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[137]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[138]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[139]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[65]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[140]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[139]

Drug(s) Affected By Fatty acid-binding protein, brain (FABP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[130]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[141]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[142]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[143]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[144]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[74]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[82]

Drug(s) Affected By Sulfotransferase 1B1 (SULT1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[146]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[147]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[131]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[148]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[149]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[150]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[151]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[152]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[152]

Drug(s) Affected By Aflatoxin B1 aldehyde reductase member 3 (AKR7A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[153]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Atazanavir	DMSYRBX	Human immunodeficiency virus infection	1C62	Approved	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[52]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[154]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[155]
7-hydroxycoumarin	DMTMNO7	Discovery agent	N.A.	Investigative	[156]

Drug(s) Affected By Apolipoprotein M (APOM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[157]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[158]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[159]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[160]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[161]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[162]

Drug(s) Affected By Beta-2-glycoprotein 1 (APOH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[163]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[164]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[166]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[119]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[167]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[168]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[169]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[170]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[171]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[172]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[173]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[174]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[175]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[176]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[177]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[177]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[177]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[178]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[179]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[180]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[181]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[182]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[183]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[92]

Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fomepizole	DM6VOWQ	Athylene glycol or methanol poisoning	NE61	Approved	[184]
Ademetionine	DMYQDBO	Hepatic fibrosis	DB93.0	Approved	[185]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[92]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[150]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[186]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[147]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[187]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[92]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[188]

Drug(s) Affected By Apolipoprotein A-IV (APOA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Fructose	DM43AN2	Vomiting	MD90	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[148]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[65]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[163]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[190]

Drug(s) Affected By Epoxide hydrolase 1 (EPHX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[191]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[150]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[192]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[193]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[195]

Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[196]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[197]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[196]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[197]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[198]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[196]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[196]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[196]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[199]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[200]

Drug(s) Affected By Aldo-keto reductase family 1 member C4 (AKR1C4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[201]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[202]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[202]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[58]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[58]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[164]
Indomethacin	DMSC4A7	Bursitis		Approved	[202]

Drug(s) Affected By Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[203]
Haloperidol	DM96SE0	Delirium		Approved	[204]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[195]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[205]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[206]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[142]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[206]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[110]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[207]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[208]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[209]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[210]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[211]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[212]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[213]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[214]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[90]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma (PPARG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[106]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[215]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[216]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[217]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[218]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[219]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[220]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[221]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[222]

Drug(s) Affected By Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial (ACADSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[223]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[224]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[195]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[225]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[226]

Drug(s) Affected By Sulfotransferase 1E1 (SULT1E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[227]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[227]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[228]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[229]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[227]
Dienestrol	DMBSXI0	Atrophic vaginitis	GA30.2	Approved	[229]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[230]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[231]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[232]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[233]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[234]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[65]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[119]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[147]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[187]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[235]

Drug(s) Affected By Apolipoprotein C-IV (APOC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[77]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[236]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[187]
Fenretinide	DMRD5SP	Macular degeneration	9B78.3	Phase 3	[237]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[238]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[239]
GW7647	DM9RD0C	Discovery agent	N.A.	Investigative	[240]
Farnesol	DMV2X1B	Discovery agent	N.A.	Investigative	[240]

Drug(s) Affected By Peroxisomal biogenesis factor 3 (PEX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[241]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[242]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[243]

Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[244]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[57]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[58]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[57]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[57]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[245]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[246]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[173]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[57]

Drug(s) Affected By Bile acid-CoA:amino acid N-acyltransferase (BAAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[247]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[147]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[235]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[248]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[249]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[250]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[251]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[252]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[253]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[214]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[254]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[255]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]

Drug(s) Affected By Acyl-CoA dehydrogenase family member 11 (ACAD11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[195]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[256]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[256]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[257]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[235]

Drug(s) Affected By ATP-binding cassette sub-family G member 8 (ABCG8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[258]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[259]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[260]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[147]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[235]

Drug(s) Affected By Angiopoietin-related protein 3 (ANGPTL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[261]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[261]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[261]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[262]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[261]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[262]
Indomethacin	DMSC4A7	Bursitis		Approved	[261]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[147]

Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[139]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[263]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[264]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[264]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[264]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[264]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[264]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[264]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[265]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[266]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[267]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[232]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[268]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[269]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[270]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[271]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[271]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[272]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[273]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[274]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[274]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[275]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[276]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[277]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[274]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[274]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[274]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[249]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[278]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[279]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[280]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[280]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[232]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[279]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[280]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[281]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[279]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[282]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[279]

Drug(s) Affected By Apolipoprotein A-I (APOA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[284]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[285]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[90]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[286]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[287]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[288]

Drug(s) Affected By Intercellular adhesion molecule 1 (ICAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[289]
Dicloxacillin	DM8EU0Z	Bacterial infection	1A00-1C4Z	Approved	[289]
Ergonovine	DM0VEC1	Postpartum haemorrhage	JA43	Approved	[92]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[290]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[291]
Mizolastine	DM1FDN8	Allergic rhinitis	CA08.0	Approved	[292]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[293]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[294]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[295]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[296]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[297]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[298]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[300]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[301]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[302]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[301]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[303]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[304]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[305]

Drug(s) Affected By C-C motif chemokine 5 (CCL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[306]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[307]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[308]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[309]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[91]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[310]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[311]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[312]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[313]

Drug(s) Affected By E-selectin (SELE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[314]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[315]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[316]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[317]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[318]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[319]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[320]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[321]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[322]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[323]

Drug(s) Affected By Nuclear receptor subfamily 1 group D member 1 (NR1D1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[297]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[324]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[325]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[326]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[327]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[328]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[329]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[330]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[331]
Methysergide	DM1EF73	Migraine	8A80	Approved	[281]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[281]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[251]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[332]

Drug(s) Affected By Cytochrome P450 7A1 (CYP7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[116]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[333]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[334]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[172]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[335]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[333]

Drug(s) Affected By Coronin-1A (CORO1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[319]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[336]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[223]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[195]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[55]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[310]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[337]

Drug(s) Affected By Nuclear receptor ROR-alpha (RORA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[338]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[213]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[130]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[339]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[340]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[341]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[342]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[65]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[343]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[344]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[345]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[346]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[347]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[348]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[349]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[350]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[351]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[352]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[353]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[354]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[355]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[356]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[357]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[358]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[359]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[360]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[361]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[362]

Drug(s) Affected By Glutamate--cysteine ligase catalytic subunit (GCLC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[363]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[364]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[121]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[365]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[91]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[366]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[367]

Drug(s) Affected By Glutamate--cysteine ligase regulatory subunit (GCLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[368]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[369]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[73]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[370]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[371]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[372]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[373]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[374]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[375]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[297]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[376]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[377]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[378]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[300]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[379]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[380]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[381]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[204]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[338]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[382]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[382]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[383]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[382]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[65]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[310]

Drug(s) Affected By Hematopoietically-expressed homeobox protein HHEX (HHEX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[384]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[385]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[386]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[387]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[388]

Drug(s) Affected By Hepatic sodium/bile acid cotransporter (SLC10A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[334]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[65]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[389]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[99]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[390]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[391]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]

Drug(s) Affected By Nuclear receptor subfamily 1 group D member 2 (NR1D2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[370]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[392]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[141]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[370]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[325]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[393]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[116]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[394]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[110]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[395]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[394]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[396]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[397]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[394]

Drug(s) Affected By Organic solute transporter subunit alpha (SLC51A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[259]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[242]

Drug(s) Affected By Organic solute transporter subunit beta (SLC51B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[398]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[259]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[399]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[400]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]

Drug(s) Affected By G-protein coupled bile acid receptor 1 (GPBAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[401]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[402]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[403]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[238]
tauroursodeoxycholic acid	DMFKRQE	Discovery agent	N.A.	Investigative	[401]

Drug(s) Affected By Scavenger receptor class B member 1 (SCARB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[404]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[405]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[397]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[213]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[406]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[407]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[408]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]

Drug(s) Affected By ATP-binding cassette sub-family C member 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[409]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[410]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[411]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[412]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[123]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[413]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[414]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[113]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[243]

Drug(s) Affected By Homeobox protein CDX-2 (CDX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[415]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[416]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[144]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[248]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[238]
SB-431542	DM0YOXQ	Pulmonary fibrosis	CB03.4	Preclinical	[417]
OXYRESVERATROL	DMN7S4L	Discovery agent	N.A.	Investigative	[418]

Drug(s) Affected By ATP-binding cassette sub-family G member 5 (ABCG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[49]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[258]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[232]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[419]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[420]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[272]
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[136]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[8]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[259]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[8]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[242]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[421]

Drug(s) Affected By Nuclear factor erythroid 2-related factor 2 (NFE2L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[422]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[423]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[424]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[425]
Selenium	DM25CGV	N. A.	N. A.	Approved	[159]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[426]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[427]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[428]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[429]

Drug(s) Affected By 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[430]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[431]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[432]
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[92]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[433]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[50]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[434]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[51]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[435]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Modulator	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[4]
Cytochrome P450 8B1 (CYP8B1)	DETL4WB	CP8B1_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Gene/Protein Processing	[6]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Drug Response	[7]
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1)	OTRI4UR1	CP8B1_HUMAN	Gene/Protein Processing	[8]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Gene/Protein Processing	[9]
Acyl-CoA dehydrogenase family member 11 (ACAD11)	OT3T9HAX	ACD11_HUMAN	Gene/Protein Processing	[9]
Aflatoxin B1 aldehyde reductase member 3 (AKR7A3)	OTW3GO4Y	ARK73_HUMAN	Gene/Protein Processing	[9]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[9]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[10]
Aldo-keto reductase family 1 member C4 (AKR1C4)	OTW2MMOF	AK1C4_HUMAN	Gene/Protein Processing	[9]
Angiopoietin-related protein 3 (ANGPTL3)	OTCD5Z9W	ANGL3_HUMAN	Gene/Protein Processing	[9]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [3] Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
• [4] Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
• [5] Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1. Biol Chem. 2019 Apr 24;400(5):625-628.
• [6] In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I. Eur J Endocrinol. 2000 Feb;142(2):200-7.
• [7] Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid. Gut. 1980 Dec;21(12):1082-6. doi: 10.1136/gut.21.12.1082.
• [8] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [9] Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
• [10] Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J. 1996 Jan 15;313 ( Pt 2)(Pt 2):373-6.
• [11] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [12] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [13] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [14] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [15] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [16] Clinical pipeline report, company report or official report of ENYO Pharma.
• [17] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [18] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [19] Clinical pipeline report, company report or official report of Metacrine.
• [20] A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52.
• [21] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [22] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [23] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [24] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [25] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [26] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [27] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [28] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [29] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [30] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [31] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [32] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [33] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [34] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [35] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [36] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [37] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [38] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [39] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [40] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [41] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [42] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [43] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [44] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [45] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [46] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [47] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [48] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [49] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [50] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [51] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [52] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [53] Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ Pollut. 2017 Jul;226:268-276.
• [54] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [55] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [56] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [57] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [58] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [59] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [60] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [61] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [62] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [63] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [64] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [65] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [66] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [67] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [68] Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
• [69] Role of calcitriol and cortisol on human adipocyte proliferation and oxidative and inflammatory stress: a microarray study. J Nutrigenet Nutrigenomics. 2008;1(1-2):30-48. doi: 10.1159/000109873. Epub 2007 Oct 16.
• [70] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [71] Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci. 2012 Apr;126(2):446-56. doi: 10.1093/toxsci/kfs011. Epub 2012 Jan 19.
• [72] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [73] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [74] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [75] Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem Pharmacol. 2005 Jun 15;69(12):1755-63. doi: 10.1016/j.bcp.2005.03.019.
• [76] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [77] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [78] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [79] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [80] Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011 Feb;53(2):548-57. doi: 10.1002/hep.24047. Epub 2010 Dec 10.
• [81] Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol. 2007 Aug 21;13(31):4230-5. doi: 10.3748/wjg.v13.i31.4230.
• [82] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [83] Antiepileptic drugs: impacts on human serum paraoxonase-1. J Biochem Mol Toxicol. 2017 Jun;31(6).
• [84] Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem J. 2003 Oct 15;375(Pt 2):275-85.
• [85] Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin Endocrinol (Oxf). 2004 Jan;60(1):75-80.
• [86] Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull. 2006 Aug;29(8):1559-63.
• [87] Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2083-9. doi: 10.1161/01.ATV.0000096207.01487.36. Epub 2003 Sep 18.
• [88] Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol. 2004 Jun;24(12):5209-22.
• [89] Transcriptional regulation of human paraoxonase 1 by PXR and GR in human hepatoma cells. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):348-54.
• [90] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [91] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [92] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [93] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [94] Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. J Pharmacol Exp Ther. 2018 Mar;364(3):452-461. doi: 10.1124/jpet.117.243105. Epub 2018 Jan 9.
• [95] Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
• [96] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [97] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [98] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [99] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [100] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [101] Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol. 2006 Nov-Dec;26(6):484-92.
• [102] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [103] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [104] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [105] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [106] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [107] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [108] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [109] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [110] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [111] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [112] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [113] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [114] Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
• [115] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [116] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [117] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [118] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [119] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [120] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [121] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [122] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [123] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [124] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [125] ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
• [126] Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
• [127] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [128] Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
• [129] Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.
• [130] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [131] Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
• [132] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [133] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [134] Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
• [135] Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
• [136] Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
• [137] Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
• [138] Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
• [139] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [140] The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15. doi: 10.1111/bph.13472. Epub 2016 Apr 8.
• [141] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [142] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [143] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [144] Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
• [145] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [146] Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
• [147] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [148] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [149] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [150] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [151] Studies on sulfation of synthesized metabolites from the local anesthetics ropivacaine and lidocaine using human cloned sulfotransferases. Drug Metab Dispos. 1999 Sep;27(9):1057-63.
• [152] Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases. Biochem Biophys Res Commun. 2000 Jan 7;267(1):80-4. doi: 10.1006/bbrc.1999.1935.
• [153] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [154] Inhibition of human carbonyl reducing enzymes by plant anthrone and anthraquinone derivatives. Chem Biol Interact. 2022 Feb 25;354:109823. doi: 10.1016/j.cbi.2022.109823. Epub 2022 Jan 21.
• [155] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [156] Hepatoprotective effect of 7-hydroxycoumarin against methyl glyoxal toxicity via activation of Nrf2. Chem Biol Interact. 2017 Oct 1;276:203-209.
• [157] Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis. 2011 Jul 5;10:112. doi: 10.1186/1476-511X-10-112.
• [158] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [159] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [160] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [161] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [162] Isobaric tags for relative and absolute quantitation-based proteomics analysis of the effect of ginger oil on bisphenol A-induced breast cancer cell proliferation. Oncol Lett. 2021 Feb;21(2):101. doi: 10.3892/ol.2020.12362. Epub 2020 Dec 8.
• [163] Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
• [164] Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
• [165] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [166] Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
• [167] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [168] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [169] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [170] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [171] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [172] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [173] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [174] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [175] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [176] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [177] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [178] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [179] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [180] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [181] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [182] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [183] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [184] Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
• [185] Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
• [186] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [187] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [188] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [189] Fructose intake increases hyperlipidemia and modifies apolipoprotein expression in apolipoprotein AI-CIII-AIV transgenic mice. J Nutr. 2002 May;132(5):918-23. doi: 10.1093/jn/132.5.918.
• [190] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [191] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [192] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [193] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [194] Sp1 and Sp3 transcription factors regulate the basal expression of human microsomal epoxide hydrolase (EPHX1) through interaction with the E1b far upstream promoter. Gene. 2014 Feb 15;536(1):135-44. doi: 10.1016/j.gene.2013.11.053. Epub 2013 Dec 4.
• [195] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [196] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [197] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [198] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [199] Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
• [200] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [201] Initro CAPE inhibitory activity towards human AKR1C3 and the molecular basis. Chem Biol Interact. 2016 Jun 25;253:60-5.
• [202] Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
• [203] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [204] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [205] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [206] Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun. 2004 Oct 22;323(3):782-8.
• [207] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [208] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [209] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [210] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [211] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [212] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [213] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [214] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [215] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [216] The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
• [217] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
• [218] Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
• [219] Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
• [220] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [221] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [222] Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
• [223] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [224] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [225] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [226] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [227] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [228] Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J Appl Toxicol. 2005 Sep-Oct;25(5):354-60.
• [229] Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase. Anal Biochem. 2006 Oct 1;357(1):85-92.
• [230] Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro. Drug Metab Dispos. 2003 Nov;31(11):1300-5.
• [231] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [232] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [233] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [234] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [235] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [236] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [237] Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR. Int J Cancer. 2006 Oct 1;119(7):1599-606.
• [238] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [239] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [240] Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells. Toxicol Appl Pharmacol. 2019 Feb 15;365:61-70.
• [241] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [242] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [243] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [244] Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
• [245] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [246] Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
• [247] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [248] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [249] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [250] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [251] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [252] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [253] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [254] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [255] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [256] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [257] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [258] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [259] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [260] Organochloride pesticides induced hepatic ABCG5/G8 expression and lipogenesis in Chinese patients with gallstone disease. Oncotarget. 2016 Jun 7;7(23):33689-702. doi: 10.18632/oncotarget.9399.
• [261] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [262] Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
• [263] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [264] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [265] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [266] Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
• [267] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [268] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [269] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [270] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [271] Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
• [272] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [273] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
• [274] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [275] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [276] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [277] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [278] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [279] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [280] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [281] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [282] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [283] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [284] Quercetin represses apolipoprotein B expression by inhibiting the transcriptional activity of C/EBP. PLoS One. 2015 Apr 15;10(4):e0121784. doi: 10.1371/journal.pone.0121784. eCollection 2015.
• [285] Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism. 2004 Jun;53(6):766-71. doi: 10.1016/j.metabol.2003.11.027.
• [286] Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. doi: 10.1161/ATVBAHA.109.192088. Epub 2009 Aug 10.
• [287] The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
• [288] Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol. 2002 Apr-Jun;1(2):85-9.
• [289] Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother. 2004 Feb;53(2):174-9. doi: 10.1093/jac/dkh056. Epub 2004 Jan 16.
• [290] Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012 Apr;26(4):1535-48. doi: 10.1096/fj.11-198184. Epub 2011 Dec 23.
• [291] The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005 Jul-Aug;26(4):292-8.
• [292] Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55 Suppl 64:17-27. doi: 10.1034/j.1398-9995.2000.00803.x.
• [293] Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: a simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001 Jun;26(2):85-93. doi: 10.1016/s0923-1811(00)00165-1.
• [294] Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy. Rom J Gastroenterol. 2003 Jun;12(2):91-5.
• [295] Some non-sensitizers upregulate CD54 expression by activation of the NLRP3 inflammasome in THP-1 cells. J Toxicol Sci. 2019;44(3):213-224. doi: 10.2131/jts.44.213.
• [296] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [297] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [298] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [299] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [300] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [301] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [302] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [303] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [304] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [305] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [306] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [307] A copper-hydrogen peroxide redox system induces dityrosine cross-links and chemokine oligomerisation. Cytokine. 2011 Dec;56(3):669-75. doi: 10.1016/j.cyto.2011.08.025. Epub 2011 Oct 1.
• [308] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [309] Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Transplant Proc. 2006 Nov;38(9):2899-904. doi: 10.1016/j.transproceed.2006.08.136.
• [310] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [311] 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol. 2005 Jul;167(1):285-98. doi: 10.1016/S0002-9440(10)62973-2.
• [312] Identification of human cell responses to benzene and benzene metabolites. Genomics. 2007 Sep;90(3):324-33.
• [313] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [314] Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
• [315] Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc Res. 2003 Feb;57(2):563-71. doi: 10.1016/s0008-6363(02)00699-5.
• [316] Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum. 2004 Oct;50(10):3286-95. doi: 10.1002/art.20518.
• [317] Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003 Nov;88(11):5341-7. doi: 10.1210/jc.2003-030724.
• [318] Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H741-7. doi: 10.1152/ajpheart.01182.2005. Epub 2006 Mar 31.
• [319] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [320] The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006 Jan 20;218(1):30-8. doi: 10.1016/j.tox.2005.09.014. Epub 2005 Nov 16.
• [321] Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
• [322] Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
• [323] Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001 Apr 1;97(7):1937-41. doi: 10.1182/blood.v97.7.1937.
• [324] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [325] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [326] Functional characterization of an orphan nuclear receptor, Rev-ErbAalpha, in chondrocytes and its potential role in osteoarthritis. Arthritis Rheum. 2006 Nov;54(11):3513-22. doi: 10.1002/art.22170.
• [327] Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol. 2006 Mar;20(3):573-83. doi: 10.1210/me.2005-0165. Epub 2005 Nov 3.
• [328] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [329] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [330] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [331] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [332] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [333] The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.
• [334] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [335] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [336] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [337] Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer. 2015 May 1;136(9):2055-64.
• [338] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [339] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [340] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [341] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [342] Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One. 2011;6(9):e25612. doi: 10.1371/journal.pone.0025612. Epub 2011 Sep 28.
• [343] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [344] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [345] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [346] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [347] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [348] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [349] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [350] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [351] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [352] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [353] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [354] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [355] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [356] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [357] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [358] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [359] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [360] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [361] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [362] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [363] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [364] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [365] Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med. 2002 Mar 1;32(5):386-93. doi: 10.1016/s0891-5849(01)00812-7.
• [366] Glycidamide and cis-2-butene-1,4-dial (BDA) as potential carcinogens and promoters of liver cancer - An in vitro study. Food Chem Toxicol. 2022 Aug;166:113251. doi: 10.1016/j.fct.2022.113251. Epub 2022 Jun 21.
• [367] Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
• [368] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [369] Essential role of Nrf2 in keratinocyte protection from UVA by quercetin. Biochem Biophys Res Commun. 2009 Sep 11;387(1):109-14. doi: 10.1016/j.bbrc.2009.06.136. Epub 2009 Jul 1.
• [370] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [371] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [372] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [373] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [374] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [375] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [376] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [377] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [378] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [379] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [380] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [381] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [382] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [383] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [384] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [385] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [386] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [387] Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
• [388] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [389] Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015 Feb 27;290(9):5673-84. doi: 10.1074/jbc.M114.602540. Epub 2014 Dec 30.
• [390] Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63. doi: 10.1124/dmd.106.010033. Epub 2006 Jul 12.
• [391] Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
• [392] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [393] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [394] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [395] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [396] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [397] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [398] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [399] Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
• [400] Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
• [401] Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 2013 Dec 3;8(12):e82086. doi: 10.1371/journal.pone.0082086. eCollection 2013.
• [402] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [403] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [404] Cigarette smoke affects keratinocytes SRB1 expression and localization via H2O2 production and HNE protein adducts formation. PLoS One. 2012;7(3):e33592. doi: 10.1371/journal.pone.0033592. Epub 2012 Mar 19.
• [405] Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol. 2008 Nov 15;181(10):7332-40. doi: 10.4049/jimmunol.181.10.7332.
• [406] Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
• [407] Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004 Feb 1;67(3):411-9. doi: 10.1016/j.bcp.2003.09.014.
• [408] Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr. 2005 Oct;135(10):2305-12. doi: 10.1093/jn/135.10.2305.
• [409] Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
• [410] Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
• [411] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [412] Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
• [413] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [414] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [415] Effect of chronic exposure to inorganic arsenic on intestinal cells. J Appl Toxicol. 2019 Jun;39(6):899-907. doi: 10.1002/jat.3778. Epub 2019 Feb 12.
• [416] Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007 Feb;28(2):488-96. doi: 10.1093/carcin/bgl176. Epub 2006 Sep 21.
• [417] Activin/nodal signaling switches the terminal fate of human embryonic stem cell-derived trophoblasts. J Biol Chem. 2015 Apr 3;290(14):8834-48.
• [418] Oxyresveratrol improves tight junction integrity through the PKC and MAPK signaling pathways in Caco-2?cells. Food Chem Toxicol. 2017 Oct;108(Pt A):203-213. doi: 10.1016/j.fct.2017.08.002. Epub 2017 Aug 2.
• [419] Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
• [420] Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
• [421] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [422] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [423] Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
• [424] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [425] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [426] Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.
• [427] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [428] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [429] P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016 Feb;88:1-12. doi: 10.1016/j.fct.2015.12.004. Epub 2015 Dec 11.
• [430] Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase-deficient cell line. Biochem J. 2009 May 13;420(2):305-15.
• [431] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [432] Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
• [433] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [434] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [435] PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 2002 Jun 5;520(1-3):177-81.